Ab Initio to Host Joint Workshop on the Future of OINDP Drug Delivery in Sydney this February

Written By PY

The future of pulmonary and nasal drug delivery is evolving - and you’re invited to be part of the conversation.

Join Aptar Pharma (NYSE: ATR), Ab Initio Pharma, and the Woolcock Institute of Medical Research for an exclusive, expert-led session in Sydney exploring the next frontier of inhaled and intranasal therapies.

This event brings together senior scientists, innovators and industry decision-makers for focused discussion on:
• Real-world challenges in inhaled and intranasal therapy development
• Advanced formulation strategies
• Drug-device integration and performance
• Translational pathways from preclinical to clinical
• Regulatory and CMC considerations

📍 Woolcock Institute of Medical Research, Macquarie Park
📅 Friday, 20 February 2026
⏰ 9:30am – 12:30pm

Attendance is strictly limited. RSVP now at https://bit.ly/4kuCbhL

PY
Previous

Ab Initio Pharma to Support Advancement of NBX-200 Following Positive Phase 1 Results
Next

Catch up with the Ab Initio Pharma team at DDL 2025